← Back to screener

Viking Therapeutics, Inc. VKTX

Rank #2073 · Nasdaq · $3.2B market cap
Audited by CBIZ CPAs P.C., no going-concern flag in the latest filing.
Score
34.7
P/E
-36.9
P/B
3.60
ROE
-9.8%
Op. Margin
–%
Debt Ratio
3%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E -36.9x, P/B 3.60x. Ranks in the top 65% of the universe.

Profitability ★☆☆☆☆
Weak

ROE -9.8%. Ranks in the top 77% of the universe.

Safety ★★★★★
Excellent

Debt ratio 3%. Ranks in the top 8% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2015$0.0B$-0.0B$-0.0B$-0.0B–-114
2016$0.0B$-0.0B$-0.0B$0.0B–77
2017$0.0B$-0.0B$-0.0B$0.0B–81
2018$0.0B$-0.0B$-0.0B$0.0B–64
2019$0.0B$-0.0B$-0.0B$0.3B–2
2020$0.0B$-0.0B$-0.0B$0.3B–3
2021$0.0B$-0.0B$-0.0B$0.2B–5
2022$0.0B$-0.1B$-0.1B$0.2B–4
2023$0.0B$-0.1B$-0.1B$0.1B–16
2024$0.0B$-0.1B$-0.1B$0.3B–6
2025$0.0B$-0.1B$-0.1B$0.9B–3

← See the full screener